BioCentury
ARTICLE | Company News

Traversa, sanofi-aventis deal

April 5, 2010 7:00 AM UTC

The companies will validate and develop Traversa's PTD-DRBD RNAi delivery technology to identify RNAi candidates. PTD-DRBD is a two component molecule containing a double-stranded RNA binding domain ...